Unihealth Hospitals FY26: Bed Count Doubled, Margins Built on Borrowed Time

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Unihealth Hospitals closed FY26 with consolidated revenue of ₹132 Cr, a 137% jump from FY25’s ₹56 Cr. Net profit nearly doubled to ₹25.8 Cr from ₹15.1 Cr. Bed capacity doubled from ~200 to ~400 across Africa and India.

The catch: this explosive growth masks structural volatility. EBITDA margin of 43% sits atop a freshly commissioned Indian facility still ramping to breakeven, an Uganda business hit by seasonal disruption, and a Tanzania expansion pending approvals. Receivables ballooned to ₹123 Cr—roughly 341 debtor days—sucking cash even as the balance sheet expanded to ₹254 Cr.

The company targets 500+ beds by FY27 close and ₹250–300 Cr revenue if execution stays on track. Management’s template: greenfield hospitals hit breakeven in 9–12 months at 50% occupancy; each 50-bed unit peaks at ₹3.5–4 cr monthly revenue by year two.

The real question: can Unihealth convert this growth thesis into durable returns, or will margin compression and working capital strain deflate it?

2. Introduction

Unihealth Hospitals sits in an unusual corner of Indian healthcare: a public company operating two hospitals in Africa (Uganda, Nigeria), launching its first Indian facility (Navi Mumbai), and chasing 1,000 beds by 2028.

Founded in 2010 as a medical tourism operator, it evolved into a hands-on hospital manager. The consolidated business (Unihealth parent plus subsidiaries in Africa, consultancy arms, and pharma distribution) is now a diversified healthcare export play.

In June 2026, two months before the close of FY26, the company commissioned UMC Hospitals Navi Mumbai (50 beds, cardiac and neuro focus). A 200-bed tertiary hospital in Nashik, Maharashtra went into construction through FY25 and is scheduled to open in early FY27. It also acquired UMC Hospital Entebbe in Uganda, boosting that nation’s bed count to 150. Tanzania’s regulatory approvals for Mwanza (20 beds) inched forward; a 100-bed brownfield takeover in Dar-es-Salaam is under legal negotiation.

The last concall summary (June 2026) revealed margin upside from mix (mature assets contributing more) offset by margin headwinds from depreciation and startup losses at new facilities. Management is banking on India’s scalable economics to reduce reliance on Uganda, which still accounts for ~75% of consolidated revenue.

3. Business Model: WTF Do They Even Do?

Unihealth operates in four lanes: (a) hospital and medical centre operations (the bulk), (b) healthcare consultancy and project management, (c) pharmaceutical and medical consumables export and distribution, and (d) medical value travel facilitation for international patients seeking surgery in India.

The hospital portfolio is deliberately curated. Africa holds two operating multi-speciality units: UMC Victoria (120 beds, Uganda) and UMC Zhahir (80 beds, Nigeria). India now has Navi Mumbai (50 beds, fresh ramp) and Nashik (200 beds, incoming). Total commissioned capacity is ~400 beds as of end-FY26.

In Africa, the company targets East Africa’s paying capacity: Uganda can sustain ~200–250 beds before market saturation hits; Tanzania and Kenya can support larger scale due to national insurance schemes and oil-linked purchasing power. The company explicitly avoids mega-hospital format in India, capping individual facilities at 50–200 beds, betting on higher service responsiveness and lower overhead vs. Apollo or Fortis.

The doctor retention play is unusual. Unihealth recruits mid-career surgeons (35–50 years old) seeking leadership visibility they can’t get in large chains. It matches infrastructure quality of big players (modular OTs, cath labs, ICU), settles doctor dues weekly rather than month-end, and staffs a full-time in-house backbone (medicine, ortho, cardiology, ICU) to de-risk post-op outcomes for visiting consultants. Navi Mumbai has already signed 130+ consultants.

Medical value travel (facilitating international patient inflows to India) was the founder’s original vertical. It remains underdeveloped operationally but strategically important: the company has 250+ live inquiries across Nigeria, Uganda, Tanzania, and Kenya, with a typical 30-day-to-6-month conversion cycle.

Pharma and consultancy account for <9% of revenue—low-margin, high-complexity, and strategically inert. The real economics are in hospital operations.

4. Financials Overview

Figures are consolidated, in ₹ crore.

FY26 revenue exploded to ₹132 Cr, driven by a full-year contribution from Uganda (growth accelerated mid-FY25), Nigeria’s continued ramp, India’s Navi Mumbai ramp-up post-February soft launch, and the Entebbe acquisition. EBITDA margin: 42.9% (pre-tax basis). Net profit margin: 19.6%.

The jump in PAT (71% vs. revenue’s 137%) reflects elevated depreciation and finance costs: FY26 depreciation jumped to ₹10.2 Cr (from ₹2.5 Cr in FY25) and interest remained at ₹2.3 Cr despite lower debt. Tax rate: 1.8%, well below statutory—benefit of low margins in prior years.

Management on the call attributed elevated FY26 margins to a mix skewed toward mature assets (Uganda Victoria, Nigeria Zhahir). As newer facilities ramp (startup losses + depreciation) and Nashik commissions, consolidated EBITDA margin will compress toward 32–33% baseline, with PAT margins settling at 8–12% during rapid expansion.

Management Concall Guidance (June 2026):

Navi Mumbai (50 beds): operational since mid-February 2026. Initial occupancy ~10% in first months; ARPOB (average revenue per occupied bed) came in at ₹32–32.5k, above management’s initial ₹27.5k plan. Breakeven target: Q2 FY27 (end-September 2026). FY27 occupancy target: 55–62%.

Nashik (200 beds): Hospital registration expected in ~5–10 days (from June call), pharmacy/imaging licenses by month-end, commissioning first week of July. Management applies a standardized greenfield ramp: month 1 occupancy ~2–3%, month 2 ~6–8%, month 4+ >10%, with empanelment ramps (3–6 months post-license for government bodies like Konkan Railways). Breakeven design point: 50% occupancy, typically 9–12 months post-commissioning. For a mature 50-bed unit: peak revenue ₹3.5–4 cr/month, EBITDA margin mid-20s at maturity.

Tanzania Mwanza (20 beds): License expected 3–4 weeks from concall date; infrastructure ready.

Tanzania Dar-es-Salaam (100-bed brownfield): Commercial terms done, legal/statutory approvals pending ~2–3 months. Rationale: immediate revenue upon takeover (running facility), then significant expansion in 2–4 quarters.

FY27 bed ambition: 420+ commissioned (Uganda 150 + Navi 50 + Nashik 200 + Mwanza 20); if Tanzania 100-bed closes, target crosses 500 beds.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market pays 29.1x reported FY26 earnings. Over five years, Unihealth’s average P/E stood at 27.8x, suggesting the current multiple sits near historical par. Among hospital peers (Apollo, Max, Fortis, Aster, Narayana Hrudayalaya, Global Health, Krishna Institute), the median P/E is 45.96x—meaning Unihealth trades at a significant discount to the larger-cap hospital chain peers.

ROE at 21.4% sits above the peer median of 13.6%, pointing to better capital efficiency. ROCE of 27.4% is the highest in the peer set—a function of the company’s smaller, asset-light model and high margins on Africa operations (though that ROCE will compress as Nashik and other greenfield assets mature and require higher capex before generating full returns).

EV/EBITDA